Search clinical trials for: induction chemotherapy (fludarabine, cytarabine, idarubicin)

Total 713 results

University of Birmingham
Jazz Pharmaceuticals; Adienne SA; IMPACT (funded by NHS Blood & Transplant, Anthony...

Active, not recruiting

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT (COSI)

Acute Myeloid Leukaemia | High-risk Myelodysplastic Syndrome

United Kingdom
The Netherlands Cancer Institute
Copenhagen University Hospital at Herlev

Active, not recruiting

Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma (TIL)

Metastatic Melanoma

Netherlands, Denmark
WiSP Wissenschaftlicher Service Pharma GmbH

Completed

Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy (DSMM-II)

Multiple Myeloma
European Mantle Cell Lymphoma Network
Lymphoma Study Association; German Low Grade Lymphoma Study Group

Unknown

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Lymphoma, Mantle-Cell

France, Germany, Poland
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Recruiting

A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors

Advanced Solid Tumors

China
University College, London

Active, not recruiting

Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (UKALL14)

Leukemia | Mucositis | Oral Complications

United Kingdom
Samsung Medical Center
Seok Jin Kim

Terminated

Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma (ZOLINZA)

Mantle Cell Lymphoma

Korea, Republic of
Kite, A Gilead Company

Terminated

Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)

Lymphoma, Non-Hodgkin

United States, Italy, Austria, Canada, France, Germany, Japan, Spain, Sweden, United Kingdom
University Hospital, Angers

Recruiting

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR (BIG-1)

Acute Myeloid Leukemia (AML)

France
University Health Network, Toronto
Takara Bio Inc.

Active, not recruiting

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Melanoma | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Bladder Cancer | Liver Cancer | Synovial Sarcoma | NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients

Canada
GlaxoSmithKline

Active, not recruiting

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Neoplasms

United States, Netherlands, Canada, United Kingdom
Memorial Sloan Kettering Cancer Center

Active, not recruiting

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Myeloid Diseases

United States
University of Michigan Rogel Cancer Center
Takeda

Withdrawn

Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States
Peking University People's Hospital

Recruiting

RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT

Myelodysplastic Syndromes | Acute Leukemia

China
Yong Chen

Recruiting

Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment

Other Disorders of Soft Tissues

China
Zhejiang Cancer Hospital

Unknown

Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

Breast Cancer

China
Sun Yat-sen University

Unknown

Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene

Lung Adenocarcinoma

China
University of Rochester

Completed

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Kidney Cancer

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

Leukemia

United States, Australia, Canada
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms | Unusual Cancers of Childhood

United States
Jonsson Comprehensive Cancer Center
Jazz Pharmaceuticals

Active, not recruiting

CPX-351 Plus Enasidenib for Relapsed AML

Recurrent Acute Myeloid Leukemia

United States
Fujian Cancer Hospital

Not yet recruiting

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Lung Adenocarcinoma | PD-1 Inhibitor | Stage IV Non-small Cell Lung Cancer | VEGF
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Hematologic Malignancies

United States
Hannover Medical School

Unknown

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Leukemia

Germany
National Cancer Institute (NCI)

Recruiting

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy | Acute Myeloid Leukemia, Myelodysplasia-Related

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Refractory Chronic... and other conditions

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

Recurrent/Refractory Malignant Lymphoma

China
China Medical University, China

Terminated

A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer

Stomach Neoplasms

China
Nantes University Hospital

Not yet recruiting

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (CY-MET-RIC)

Hematologic Malignancy | Graft Versus Host Disease
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Juvenile Myelomonocytic Leukemia

United States
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Fudan University; Medpace, Inc.

Unknown

Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients

Hepatocellular,Carcinoma

China
Therapeutic Advances in Childhood Leukemia Consortium

Completed

Epigenetic Reprogramming in Relapse/Refractory AML

Acute Myelogenous Leukemia

United States, Canada, Australia
Peking University People's Hospital

Recruiting

RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT

Myelodysplastic Syndromes

China
The First Affiliated Hospital with Nanjing Medical...

Enrolling by invitation

Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Asan Medical Center

Enrolling by invitation

A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma (IVAM)

Diffuse Large B Cell Lymphoma
Allogene Therapeutics

Active, not recruiting

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma (ALPHA)

Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Large B Cell Lymphoma

United States
Barretos Cancer Hospital

Completed

Induction Chemotherapy for Advanced Head and Neck Cancer

Head and Neck Cancer

Brazil
National Cancer Institute (NCI)

Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Puerto Rico
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma | ALL, Adult | Philadelphia-Positive Acute Lymphoblastic Leukemia

China
Universitätsklinikum Hamburg-Eppendorf
Deutsche Kinderkrebsstiftung

Active, not recruiting

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

Brain Tumors

Germany, Denmark, United Kingdom, Belgium, Poland, Ireland, Austria, Italy, Czechia, France, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland
Jennifer Crombie, MD
Merck Sharp & Dohme LLC

Recruiting

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Primary Mediastinal Large B Cell Lymphoma | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma Refractory | Primary Mediastinal Large B-Cell Lymphoma Recurrent | Epstein-Barr Virus Positive Diffuse Large...

United States
Henan Cancer Hospital

Recruiting

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Non-hodgkin Lymphoma,B Cell

China
Institute of Hematology & Blood Diseases Hospital
Hangzhou Qihan Biotech Co.,Ltd.

Not yet recruiting

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Minimal Residual Disease | AML, Adult

China
M.D. Anderson Cancer Center
Eisai Inc.

Completed

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

Leukemia

United States
National Cancer Institute (NCI)

Completed

Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States
Amgen

Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (MENDEL-2)

Hyperlipidemia

United States, Denmark, Taiwan, Korea, Republic of, Australia, Belgium, Canada, South Africa, France, Turkey
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Withdrawn

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | CNS 2a | CNS 2b | CNS 2c | CNS1
Simcere Pharmaceutical Co., Ltd

Unknown

A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

China

Search clinical trials for: induction chemotherapy (fludarabine, cytarabine, idarubicin)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations